←
Daniel Ma526 posts
Daniel Ma avatar✓

Daniel Ma ✓

@DanielMaMD

Enterprise Head & Neck Disease Group Chair @MayoCancerCare. Head & Neck Division Chair @MayoRadOnc.

◷ Joined October 2019▧ 50 Photos and videos
Mayo Clinic Radiation Oncology avatar
⟳ Daniel Ma retweeted
Mayo Clinic Radiation Oncology@MayoRadOnc·Sep 27

In our professional lives, we may get only one opportunity to truly advance the field in a meaningful way. Fully realizing an opportunity like that requires a focused, dedicated team working collaboratively toward a shared goal.

Post attachmentPost attachmentPost attachmentPost attachment
C. Jillian Tsai, MD, PhD avatar
⟳ Daniel Ma retweeted
C. Jillian Tsai, MD, PhD@CJTsaiMDPhD·15 Oct 2025

🗣️☢️Intriguing abstract #ESMO25 - possible increased systemic response after hypofractionated RT (36Gy/12fx) with pembro for R/M-HNSCC? Looking forward to more details!

Post attachment
Daniel Ma avatar
Daniel Ma@DanielMaMD·30 Sep 2025

Great work by @MayoRadOnc emphasizing our specialty’s need to engage with the cultural perception of radiation. Congrats to Drs. Elsa Sutton, Scott Lester, and the study team for this unique perspective. #ASTRO2025

Post attachment
Daniel Ma avatar
Daniel Ma@DanielMaMD·11 Sep 2025

4b. In this context, DART provides an alternative between "watchful waiting" and "nuke it from orbit, it's the only way to be sure." Absolute radiation dose is important. 30 Gy demonstrated persistent QOL benefits at 2 yrs, something 50 Gy did not.

Daniel Ma avatar
Daniel Ma@DanielMaMD·11 Sep 2025

4a. Regardless of how you feel about TORS, you will see adjuvant patients in your referrals. Having adjuvant options is important. Particularly in the eternal tumor board discussion on what to do pts with only 1-2 int risk factors after surgery.

Daniel Ma avatar
Daniel Ma@DanielMaMD·11 Sep 2025

3. Several commentators stated that they would prefer no TORS altogether. Seeing the outcomes in our pts, I can unequivocally say that had I earlier stage HPVOPSCC, I would want TORS followed by DART for myself rather than 70 or even 60 Gy of CRT.

Daniel Ma avatar
Daniel Ma@DanielMaMD·11 Sep 2025

2. ENE- patients. Given the excellent PFS, now in both 1273 and 1675, and the large difference in acute toxicity, late toxicity, and QOL, we do offer DART off trial to patients with int risk disease. DART 2.0's focus will be selecting which of these patients can be observed.

Daniel Ma avatar
Daniel Ma@DanielMaMD·11 Sep 2025

So what are our final thoughts: 1. ENE+ patients. Adjuvant de-escalation without biologic selection is not ready for prime time. @DavidRoutmanMD and DART 2.0 will hopefully answer some of these questions with ctDNA.

Daniel Ma avatar
Daniel Ma@DanielMaMD·11 Sep 2025

Absolute numbers for recurrence were small, so perhaps we were unlucky. But it's challenging for me to reconcile a difference in primarily distant control based upon differences in locoregional RT dose. I would stress our thoughts on cis vs doce are hypothesis generating.

Daniel Ma avatar
Daniel Ma@DanielMaMD·11 Sep 2025

The juicy bit is of course the ENE+ cohort, particularly the AJCC 8 pN2. I dont' know if cis meaningfully improves distant control for the ENE+ and pN2 pts. Like Dr. Sher says, this goes against much of the established HN literature.

Daniel Ma avatar
Daniel Ma@DanielMaMD·11 Sep 2025

We were very happy to find a SS difference in grade 3 toxicity, and also like David points out a large difference in grade 2 toxicity. This is reflected in SS differences in patient QOLs even at 2 years. Take home: grade 2s really do matter.